AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15119721 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26 with lateral condensation
Number of subjects: 940
Study 15119721 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus with lateral condensation
Number of subjects: 940
Study 15119721 — intervention group
Group type: EXPERIMENTAL
Intervention: AH 26 with hybrid condensation
Number of subjects: 940
Study 15119721 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus with hybrid condensation
Number of subjects: 940
Study 15119721 — intervention group
Group type: COMPARATOR
Intervention: Thermafil
Number of subjects: 940
Study 15119721 — intervention group
Group type: COMPARATOR
Intervention: Hybrid condensation
Number of subjects: 940
Study 15119721 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation
Number of subjects: 940
Study 11468200 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (180 microgram/kg bolus and 2.0 microgram/kg per minute infusion for 72 hours)
Number of subjects: 98
Study 11468200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 9491878 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 70
Study 9491878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8312416 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 U subcutaneously once a week
Number of subjects: 41
Study 8312416 — intervention group
Group type: EXPERIMENTAL
Intervention: 9000 U subcutaneously once a week
Number of subjects: 41
Study 8312416 — intervention group
Group type: EXPERIMENTAL
Intervention: 12000 U subcutaneously once a week
Number of subjects: 41
Study 8312416 — intervention group
Group type: EXPERIMENTAL
Intervention: 6000 U subcutaneously once every 2 weeks
Number of subjects: 41
Study 8312416 — intervention group
Group type: EXPERIMENTAL
Intervention: 9000 U subcutaneously once every 2 weeks
Number of subjects: 41
Study 8312416 — intervention group
Group type: EXPERIMENTAL
Intervention: 12000 U subcutaneously once every 2 weeks
Number of subjects: 41
Study 3338011 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil) with or without tamoxifen
Number of subjects: 46
Study 3338011 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil) with tamoxifen
Number of subjects: 46
Study 3338011 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, Adriamycin, and 5-fluorouracil)
Number of subjects: 46
Study 29395560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask during 6MWT
Number of subjects: 44
Study 29395560 — intervention group
Group type: COMPARATOR
Intervention: No surgical mask during 6MWT
Number of subjects: 44
Study 26849256 — intervention group
Group type: EXPERIMENTAL
Intervention: Welding fumes containing zinc
Number of subjects: 15
Study 26849256 — intervention group
Group type: EXPERIMENTAL
Intervention: Welding fumes containing copper
Number of subjects: 15
Study 26849256 — intervention group
Group type: EXPERIMENTAL
Intervention: Welding fumes containing both copper and zinc
Number of subjects: 15
Study 25600160 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables (model 1)
Number of subjects: 623
Study 25600160 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL-scores (model 2)
Number of subjects: 623
Study 25600160 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 623
Study 24429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 μg + vilanterol 25 μg
Number of subjects: 3255
Study 24429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg + vilanterol 25 μg
Number of subjects: 3255
Study 24429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg + vilanterol 25 μg
Number of subjects: 3255
Study 24429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50 μg + vilanterol 25 μg (pooled analysis)
Number of subjects: 3255
Study 24429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg + vilanterol 25 μg (pooled analysis)
Number of subjects: 3255
Study 24429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 200 μg + vilanterol 25 μg (pooled analysis)
Number of subjects: 3255
Study 24429127 — intervention group
Group type: COMPARATOR
Intervention: Vilanterol only
Number of subjects: 3255
Study 21903957 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation (25 g daily for 2.7 years)
Number of subjects: 350
Study 21903957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 21903957 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone soy protein (ISP) supplementation (25 g daily for 2.7 years) in women <5 years postmenopausal
Number of subjects: 350
Study 21903957 — intervention group
Group type: COMPARATOR
Intervention: Placebo in women <5 years postmenopausal
Number of subjects: 350
Study 19086328 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab monotherapy
Number of subjects: 463
Study 19086328 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (control group)
Number of subjects: 463
Study 17030766 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 17030766 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 12806269 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of eating behavior and satiety, supply of warmth, reduction of physical hyperactivity, and restoration of social activities
Number of subjects: 0
Study 12806269 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants (SSRIs)
Number of subjects: 0
Study 10450292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet (rich in fruits, vegetables, and low-fat dairy products)
Number of subjects: 459
Study 10450292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 459
Study 10450292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet (in participants with hypertension)
Number of subjects: 459
Study 10450292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet (in participants without hypertension)
Number of subjects: 459
Study 10450292 — intervention group
Group type: EXPERIMENTAL
Intervention: Minority subgroup analysis
Number of subjects: 459
Study 8738446 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceful epidural corticosteroid injections (125 mg prednisolone acetate + 40 ml saline)
Number of subjects: 60
Study 8738446 — intervention group
Group type: COMPARATOR
Intervention: Control group (125 mg prednisolone acetate alone)
Number of subjects: 60
Study 8738446 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceful epidural corticosteroid injections
Number of subjects: 60
Study 8738446 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 2018658 — intervention group
Group type: EXPERIMENTAL
Intervention: STH + CP (creatine phosphate 10.0 mmol/l)
Number of subjects: 50
Study 2018658 — intervention group
Group type: COMPARATOR
Intervention: STH (control group)
Number of subjects: 50
Study 6129674 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 22
Study 6129674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31607387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose of 500 mg and continuous infusion of 250 mg h‐1)
Number of subjects: 100
Study 31607387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31607387 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100
Study 29850764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warning
Number of subjects: 2149
Study 29850764 — intervention group
Group type: COMPARATOR
Intervention: Text-only warning
Number of subjects: 2149
Study 28277823 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil (VCO)
Number of subjects: 12
Study 28277823 — intervention group
Group type: COMPARATOR
Intervention: Safflower Oil (SO)
Number of subjects: 12
Study 25365652 — intervention group
Group type: EXPERIMENTAL
Intervention: Block Allograft (BA)
Number of subjects: 16
Study 25365652 — intervention group
Group type: COMPARATOR
Intervention: Sandwich Bone Augmentation (SBA)
Number of subjects: 16
Study 25365652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 24707200 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep tissue massage (DTM)
Number of subjects: 59
Study 24707200 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy of DTM and NSAID
Number of subjects: 59
Study 22960162 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational coaching at home and by phone with a health educator, mailed educational materials, and weekly text messages for 6 months.
Number of subjects: 121
Study 22960162 — intervention group
Group type: COMPARATOR
Intervention: Control condition (details not specified).
Number of subjects: 121
Study 20071900 — intervention group
Group type: EXPERIMENTAL
Intervention: Koryo Hand Therapy (KHT), applied three times a week for 8 weeks
Number of subjects: 45
Study 20071900 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 45
Study 17395516 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly medical support through SMS based upon weekly review of glucose values
Number of subjects: 30
Study 17395516 — intervention group
Group type: COMPARATOR
Intervention: No SMS (self‐monitored blood glucose values downloaded weekly without SMS)
Number of subjects: 30
Study 17395516 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS sequence
Number of subjects: 30
Study 17395516 — intervention group
Group type: COMPARATOR
Intervention: No SMS period
Number of subjects: 30
Study 15530684 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 550
Study 15530684 — intervention group
Group type: COMPARATOR
Intervention: Td vaccine
Number of subjects: 550
Study 11642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitisation to dust mite
Number of subjects: 3985
Study 11642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitisation to cat
Number of subjects: 3985
Study 11642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitisation to grass pollen
Number of subjects: 3985
Study 11642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitisation to birch pollen (in Austria)
Number of subjects: 3985
Study 11642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitisation to parietaria (in Greece)
Number of subjects: 3985
Study 11642579 — intervention group
Group type: COMPARATOR
Intervention: Comparative analysis of asthma and hay fever risk
Number of subjects: 3985
Study 11642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of dust mite allergy
Number of subjects: 3985
Study 11642579 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk of cat and grass pollen allergy
Number of subjects: 3985
Study 10102965 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day therapy with ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d.
Number of subjects: 105
Study 10102965 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day therapy with ranitidine bismuth citrate 400 mg b.d., metronidazole 500 mg b.d. and tetracycline 500 mg b.d.
Number of subjects: 105
Study 7778649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle endocervical aspiration (n = 24)
Number of subjects: 52
Study 7778649 — intervention group
Group type: COMPARATOR
Intervention: Kevorkian curette (n = 28)
Number of subjects: 52
Study 2185825 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize starch paste with 240 g amylose/kg (S24)
Number of subjects: 9
Study 2185825 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize starch paste with 500 g amylose/kg (S50)
Number of subjects: 9
Study 2185825 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (GS)
Number of subjects: 9
Study 6109469 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg body weight) injected over 60 seconds
Number of subjects: 0
Study 6109469 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.15 mg/kg body weight) injected over 15 seconds
Number of subjects: 0
Study 29029135 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150mg once daily for 7 days
Number of subjects: 24
Study 29029135 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg once daily for 7 days
Number of subjects: 24
Study 29029135 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150mg once daily plus Dolutegravir 50mg once daily for 7 days
Number of subjects: 24
Study 29029135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 27459502 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle modification program (1 individual session, 5 group sessions, 2 telephone sessions)
Number of subjects: 573
Study 27459502 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based lifestyle modification program
Number of subjects: 573
Study 27459502 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study 24732833 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated technique (3D fluoroscopy-based)
Number of subjects: 21
Study 24732833 — intervention group
Group type: COMPARATOR
Intervention: Non-navigated technique (2D fluoroscopy-guided)
Number of subjects: 21
Study 22708417 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (PT) combined with standard pharmacotherapy and respiratory training
Number of subjects: 112
Study 22708417 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy
Number of subjects: 112
Study 20484089 — intervention group
Group type: COMPARATOR
Intervention: DA (Decision Aid)
Number of subjects: 137
Study 20484089 — intervention group
Group type: EXPERIMENTAL
Intervention: DA + VC (Decision Aid + Values Clarification)
Number of subjects: 137
Study 18842422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 21
Study 18842422 — intervention group
Group type: COMPARATOR
Intervention: Unstable angina
Number of subjects: 21
Study 18842422 — intervention group
Group type: COMPARATOR
Intervention: Control (stable patients)
Number of subjects: 21
Study 18842422 — intervention group
Group type: COMPARATOR
Intervention: Control (unstable patients)
Number of subjects: 21
Study 15974417 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine (10 mg morphine hydrochloride with Intrasite Gel)
Number of subjects: 24
Study 15974417 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Intrasite Gel with placebo)
Number of subjects: 24
Study 12902209 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drugs FDC
Number of subjects: 42
Study 12902209 — intervention group
Group type: EXPERIMENTAL
Intervention: Four drugs FDC
Number of subjects: 42
Study 12902209 — intervention group
Group type: COMPARATOR
Intervention: WHO simplified protocol
Number of subjects: 42
Study 10826029 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused psychosocial intervention for stroke survivors
Number of subjects: 0
Study 8863695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive urinary kallikrein: creatinine ratio (IUK:Cr)
Number of subjects: 459
Study 8863695 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin sensitivity test (AST)
Number of subjects: 459
Study 8863695 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (60 mg)
Number of subjects: 459
Study 1296495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioversol 350
Number of subjects: 0
Study 1296495 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 350
Number of subjects: 0
Study 6094443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g im or iv on call to the operating room)
Number of subjects: 178
Study 6094443 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (2 g im or iv on call to the operating room, followed by 2 g intravenously at 6 hourly intervals for up to 24 h)
Number of subjects: 178
Study 2948731 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/m2 5'‐dFUrd
Number of subjects: 18
Study 2948731 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/m2 5'‐dFUrd
Number of subjects: 18
Study 2948731 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐dFUrd
Number of subjects: 18
Study 29733038 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of depression using the MADRS-S depression scale during GP visits at baseline and at visits 4, 8, and 12 weeks.
Number of subjects: 183
Study 29733038 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of depression using the MADRS-S depression scale during GP visits.
Number of subjects: 183
Study 29733038 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (control group).
Number of subjects: 183
Study 27718781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg per day, 4-weeks-on, 2-weeks-off for 1 year)
Number of subjects: 615
Study 27718781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 27718781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 615
Study 24511614 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy labelling
Number of subjects: 329
Study 24511614 — intervention group
Group type: EXPERIMENTAL
Intervention: Single traffic light labelling
Number of subjects: 329
Study 24511614 — intervention group
Group type: COMPARATOR
Intervention: No-label control
Number of subjects: 329
Study 22236951 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsa dancing (8-week progressive programme)
Number of subjects: 28
Study 22236951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 19720471 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief risk reduction counseling (BRRC)
Number of subjects: 4298
Study 19720471 — intervention group
Group type: COMPARATOR
Intervention: Informational condition
Number of subjects: 4298
Study 18551108 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 48
Study 18551108 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exercise (EX)
Number of subjects: 48
Study 18551108 — intervention group
Group type: COMPARATOR
Intervention: Baseline weight gain on weekends
Number of subjects: 48
Study 15742089 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 30
Study 15742089 — intervention group
Group type: EXPERIMENTAL
Intervention: Free running exercise challenge
Number of subjects: 30
Study 15742089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise challenge
Number of subjects: 30
Study 14556925 — intervention group
Group type: EXPERIMENTAL
Intervention: Glufosfamide (5 g/m²) administered via 1-hour intravenous infusion every 3 weeks
Number of subjects: 35
Study 14556925 — intervention group
Group type: COMPARATOR
Intervention: Active-hydration
Number of subjects: 35
Study 10759342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus Pindolol (FLX + PIN)
Number of subjects: 111
Study 10759342 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine plus Placebo (FLX + PLA)
Number of subjects: 111
Study 8636433 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 6
Study 8636433 — intervention group
Group type: COMPARATOR
Intervention: Control (no IL-2 therapy)
Number of subjects: 6
Study 1467895 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin staples
Number of subjects: 48
Study 1467895 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular polydioxanone sutures
Number of subjects: 48
Study 6731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin (2 mg/kg)
Number of subjects: 10
Study 6731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.2 mg/kg)
Number of subjects: 10
Study 6731261 — intervention group
Group type: COMPARATOR
Intervention: Control (before treatment)
Number of subjects: 10
Study 6731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after Trimazosin
Number of subjects: 10
Study 6731261 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise after Propranolol
Number of subjects: 10
Study 31830830 — intervention group
Group type: COMPARATOR
Intervention: Blood Flow Restricted Resistance Exercise (BFRRE)
Number of subjects: 36
Study 31830830 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 36
Study 29794048 — intervention group
Group type: EXPERIMENTAL
Intervention: Social condition (public evaluations)
Number of subjects: 878
Study 29794048 — intervention group
Group type: COMPARATOR
Intervention: Asocial condition (private evaluations)
Number of subjects: 878
Study 29794048 — intervention group
Group type: EXPERIMENTAL
Intervention: Social condition first followed by asocial condition
Number of subjects: 878
Study 29794048 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformity and self-consistency mechanisms
Number of subjects: 878
Study 29794048 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in conformity
Number of subjects: 878
Study 26609008 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (AA) 1 g plus prednisone 5 mg twice daily
Number of subjects: 2044
Study 26609008 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone
Number of subjects: 2044
Study 25443601 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga based cardiac rehabilitation program
Number of subjects: 250
Study 25443601 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy based program
Number of subjects: 250
Study 22158680 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 (2 manufacturers)
Number of subjects: 800
Study 22158680 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV3 (1 manufacturer)
Number of subjects: 800
Study 22158680 — intervention group
Group type: COMPARATOR
Intervention: tOPV
Number of subjects: 800
Study 21702260 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy without drainage
Number of subjects: 212
Study 21702260 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy with intra-peritoneal drain
Number of subjects: 212
Study 17685870 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapies (anti-vascular endothelial growth factor strategies, anti-inflammatory agents, gene therapy, and stem cell therapy)
Number of subjects: 0